Cover Image

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Parkinson's disease (PD) poses a significant therapeutic challenge, mainly due to the limited ability of drugs to cross the blood-brain barrier (BBB) without undergoing metabolic transformations. Levodopa, a key component of dopamine replacement therapy, effectively enhances dopaminergic activi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kaili Liang (Author), Li Yang (Author), Jiawei Kang (Author), Bo Liu (Author), Ding Zhang (Author), Liyan Wang (Author), Wei Wang (Author), Qing Wang (Author)
Format:	Book
Published:	Elsevier, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levodopa versus levodopa sparing in early parkinson's disease: can we meet halfway?
by: Mayela Rodríguez-Violante, et al.
Published: (2024)

In situ thermosensitive gel of levodopa: Potential formulation for nose to brain delivery in Parkinson disease
by: Shohreh Alipour, et al.
Published: (2020)

Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment
by: Fu XX, et al.
Published: (2022)

Levodopa-induced Dyskinesias in Parkinson's Disease: Current Knowledge and Future Scenarios
by: Francesca Morgante
Published: (2015)

Parkinson's disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010)

Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis
by: Amélie Marsot, et al.
Published: (2017)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018)

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson's Disease
by: Alfonsina Tirozzi, et al.
Published: (2021)

Design and Application of Near-Infrared Nanomaterial-Liposome Hybrid Nanocarriers for Cancer Photothermal Therapy
by: Pan Liang, et al.
Published: (2021)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
by: Annus Á, et al.
Published: (2017)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
by: Faddoul L, et al.
Published: (2018)

The roles of astrocytic phagocytosis in maintaining homeostasis of brains
by: Se Young Lee, et al.
Published: (2021)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa-Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats
by: Wen-Wen Wang, et al.
Published: (2019)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease
by: Marianne Luinstra, et al.
Published: (2019)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018)

Dramatic Improvement in Juvenile Parkinsonism after Levodopa Treatment in a Patient Negative for the PANK2 Mutation
by: Syuan-Yu Hong, et al.
Published: (2016)

Istradefylline: A novel agent in the treatment of "off" episodes associated with levodopa/carbidopa use in Parkinson disease
by: Lauren Cummins, et al.
Published: (2022)

Immunogenic Cell Death Photothermally Mediated by Erythrocyte Membrane-Coated Magnetofluorescent Nanocarriers Improves Survival in Sarcoma Model
by: Ailton Antonio Sousa-Junior, et al.
Published: (2023)

Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases
by: Anjali Bhosale, et al.
Published: (2023)

Phagocytosis Main Key of Immune System
Published: (2023)

Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma
by: Wenguang Gu, et al.
Published: (2019)

Levodopa-based device-aided therapies for the treatment of advanced Parkinson's disease: a social return on investment analysis
by: Inez Denham, et al.
Published: (2024)

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease
by: Debleena Guin, et al.
Published: (2017)

Large left posterior fossa meningioma presenting with quadriplegia in a woman with history of carbidopa-levodopa resistant parkinsonism
by: Antonio Jose Reyes, et al.
Published: (2019)

Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies
by: Anders Thorsted, et al.
Published: (2023)

Regulators of phagocytosis as pharmacologic targets for stroke treatment
by: Jian Cheng, et al.
Published: (2023)

Benefit of a Short Chain Peptide as a Targeting Ligand of Nanocarriers for a Brain-Driven Purpose
by: Yu-Chen Lo, et al.
Published: (2021)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016)

Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real‐world Unified Parkinson's Disease Rating Scale
by: Dongwoo Chae, et al.
Published: (2021)

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
by: Ritam Bandopadhyay, et al.
Published: (2022)

Effects of blackberry (Morus nigra) fruit juice on levodopa-induced dyskinesia in a mice model of Parkinson's disease
by: Fahimi Z, et al.
Published: (2018)

Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience
by: Szabolcs Szatmári, et al.
Published: (2024)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
by: József Attila Szász, et al.
Published: (2022)

Peptide Functionalization of Emulsion-Based Nanocarrier to Improve Uptake across Blood-Brain Barrier
by: Alberta De Capua, et al.
Published: (2024)

pH-Responsive Dual Drug-Loaded Nanocarriers Based on Poly (2-Ethyl-2-Oxazoline) Modified Black Phosphorus Nanosheets for Cancer Chemo/Photothermal Therapy
by: Nansha Gao, et al.
Published: (2019)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
by: Urszula Adamiak-Giera, et al.
Published: (2021)

A Knowledge-Driven Framework Discovers Brain ACtivation-Transition-Spectrum (ACTS) Features for Parkinson’s Disease
by: Jiewei Lu, et al.
Published: (2024)